Business Case

Identified and mapped KOLs and COEs, and assessed therapeutic approach and drivers of adoption to inform launch strategy for a mid-sized pharmaceutical company seeking to launch internationally

Our client, a mid-sized pharmaceutical company, was preparing to launch a treatment for ADA-SCID internationally and needed insights into the landscape of treating centers and KOLs launch countries to inform targeting and messaging. LSC was able to quickly analyze the treatment landscape, identifying and speaking with several KOLs and developing prioritized centers of excellence to target for launch. The analysis was especially catered toward physicians and centers experienced with enzyme replacement therapies and had a concentration of enzyme replacement therapy-eligible patients in the surrounding region. Based on this analysis, LSC developed tailored recommendations on potential compliant medical information activities to enhance the product’s adoption across the specified countries.